News and Announcements
Sementis Ltd – CEO Interview
- Published November 13, 2014 11:53AM UTC
- Publisher Wholesale Investor
- Categories Executive Interviews
Sementis is a biotech company developing vaccines for peanut allergy and chikungunya (like dengue fever, a mosquito-borne disease spreading throughout the world). There is an early stage pipeline for vaccines for Ebola, Q Fever, Melanoma (skin Cancer) and prostate Cancer.
The vaccines use Sementis’ “SCV” backbone technology. This is a vaccinia virus (which is also a smallpox vaccine) genetically altered to prevent replication in human cells thus ensuring safety and, through further manipulation, able to increase its immune stimulating properties. The genes for antigens from diseases are added to the SCV, which, with vaccination, elicits an immune response to the disease state in the human body.
Sementis’ Non-executive Chairman, Maurice O’Shannassy spent 25 years in the financial services industry in Australia, the United Kingdom and Asia. His most recent role was that of CEO of BlackRock Investment Management in Australia. Prior to that he was the CEO and CIO of the Asian operations of BlackRock’s antecedents, Merrill Lynch Investment Management and Mercury Asset Management.
Please listen to Sementis’ Non-executive Chairman, Mr. Maurice O’Shannassy.
Executive Interviews
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Beyond the Drip: Elemental IV’s Infrastructure Play for a Fragile Supply Chain
In the high-stakes world of life sciences, we often hunt for the next “miracle molecule” or gene-editing breakthrough. But Storme Paes, Founder and Commercial Director of Elemental IV, found her mission in something far more fundamental, yet dangerously overlooked: a simple bag of saltwater. The “Meeting Room” Revelation The genesis of Elemental IV didn’t occur […]
Backed By Leading Investment Groups and Family Offices
